Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Carcinoma, Non-Small-Cell Lung 200Neoplasms 116Breast Neoplasms 112Colorectal Neoplasms 97Ovarian Neoplasms 78Prostatic Neoplasms 75Neoplasm Metastasis 74Lung Neoplasms 66Multiple Myeloma 64Squamous Cell Carcinoma of Head and Neck 49Pancreatic Neoplasms 48Endometrial Neoplasms 48Recurrence 46Stomach Neoplasms 39Carcinoma, Renal Cell 39Small Cell Lung Carcinoma 38Melanoma 38Leukemia, Lymphocytic, Chronic, B-Cell 38Leukemia, Myeloid, Acute 34Lymphoma, Non-Hodgkin 30Urinary Bladder Neoplasms 29Parkinson Disease 4, Autosomal Dominant Lewy Body 29Triple Negative Breast Neoplasms 28Head and Neck Neoplasms 26Carcinoma, Hepatocellular 26Lymphoma, Large B-Cell, Diffuse 25Lymphoma, Follicular 25Esophageal Neoplasms 24Advanced Solid Tumors 24Lymphoma 23

Interventions

nilotinib 2asciminib 2bosutinib 1Imatinib Mesylate 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Philadelphia Chromosome × 30 days × Clear all
NCT04971226 2026-06-05

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05456191 2026-05-27

ASC4START

Novartis

Phase 3 Active not recruiting
568 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡